ECSP21079422A - Método para preparar formulaciones de péptidos estables - Google Patents
Método para preparar formulaciones de péptidos establesInfo
- Publication number
- ECSP21079422A ECSP21079422A ECSENADI202179422A ECDI202179422A ECSP21079422A EC SP21079422 A ECSP21079422 A EC SP21079422A EC SENADI202179422 A ECSENADI202179422 A EC SENADI202179422A EC DI202179422 A ECDI202179422 A EC DI202179422A EC SP21079422 A ECSP21079422 A EC SP21079422A
- Authority
- EC
- Ecuador
- Prior art keywords
- preparing stable
- peptide formulations
- stable peptide
- preparing
- powder formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000843 powder Substances 0.000 abstract 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un método mejorado para preparar una formulación en polvo que contiene un péptido. La presente invención también proporciona un método mejorado para preparar una formulación en polvo que contiene glucagón o un análogo de glucagón, en donde dicha formulación en polvo es adecuada para administración nasal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839246P | 2019-04-26 | 2019-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21079422A true ECSP21079422A (es) | 2021-11-30 |
Family
ID=70554273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202179422A ECSP21079422A (es) | 2019-04-26 | 2021-10-26 | Método para preparar formulaciones de péptidos estables |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12508229B2 (es) |
| EP (1) | EP3958838B1 (es) |
| JP (2) | JP7245926B2 (es) |
| KR (1) | KR102832458B1 (es) |
| CN (1) | CN113727700B (es) |
| AR (1) | AR118690A1 (es) |
| AU (1) | AU2020261941B2 (es) |
| BR (1) | BR112021018325A2 (es) |
| CA (1) | CA3134757A1 (es) |
| CL (1) | CL2021002690A1 (es) |
| CO (1) | CO2021014034A2 (es) |
| EA (1) | EA202192475A1 (es) |
| EC (1) | ECSP21079422A (es) |
| IL (1) | IL286426B2 (es) |
| MA (1) | MA55757A (es) |
| MX (1) | MX2021012852A (es) |
| PE (1) | PE20212368A1 (es) |
| PH (1) | PH12021552708A1 (es) |
| SG (1) | SG11202110413YA (es) |
| TW (1) | TWI771669B (es) |
| UA (1) | UA129294C2 (es) |
| WO (1) | WO2020219391A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116718762B (zh) * | 2023-06-09 | 2025-01-24 | 上海品峰医疗科技有限公司 | 一种多肽类样本稳定剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| DK49791D0 (da) | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
| WO2003066669A2 (en) | 2002-02-04 | 2003-08-14 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| US20060074025A1 (en) | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
| CN102282167B (zh) | 2008-12-15 | 2014-08-13 | 西兰制药公司 | 胰高血糖素类似物 |
| ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9610329B2 (en) | 2009-10-22 | 2017-04-04 | Albireo Pharma, Inc. | Stabilized glucagon solutions |
| CN102933598A (zh) | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| KR20140043793A (ko) * | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| IN2014CN04401A (es) | 2011-12-23 | 2015-09-04 | Zealand Pharma As | |
| FI124134B (en) | 2012-07-02 | 2014-03-31 | One Way Sport Oy | Binding between a ski and a ski boot |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9018162B2 (en) * | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| BR112017014994B1 (pt) * | 2015-02-17 | 2023-12-19 | Eli Lilly And Company | Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal |
| KR20180037994A (ko) * | 2015-07-28 | 2018-04-13 | 오토노미, 인코포레이티드 | TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법 |
| JP7001584B2 (ja) * | 2015-09-04 | 2022-01-19 | ラティチュード ファーマシューティカルズ インコーポレイテッド | 安定化されたグルカゴン溶液 |
-
2020
- 2020-04-14 TW TW109112446A patent/TWI771669B/zh active
- 2020-04-15 AR ARP200101057A patent/AR118690A1/es unknown
- 2020-04-20 CN CN202080027937.1A patent/CN113727700B/zh active Active
- 2020-04-20 WO PCT/US2020/028988 patent/WO2020219391A1/en not_active Ceased
- 2020-04-20 UA UAA202105544A patent/UA129294C2/uk unknown
- 2020-04-20 IL IL286426A patent/IL286426B2/en unknown
- 2020-04-20 EP EP20724361.9A patent/EP3958838B1/en active Active
- 2020-04-20 MA MA055757A patent/MA55757A/fr unknown
- 2020-04-20 EA EA202192475A patent/EA202192475A1/ru unknown
- 2020-04-20 SG SG11202110413YA patent/SG11202110413YA/en unknown
- 2020-04-20 JP JP2021560275A patent/JP7245926B2/ja active Active
- 2020-04-20 PH PH1/2021/552708A patent/PH12021552708A1/en unknown
- 2020-04-20 US US17/606,214 patent/US12508229B2/en active Active
- 2020-04-20 MX MX2021012852A patent/MX2021012852A/es unknown
- 2020-04-20 CA CA3134757A patent/CA3134757A1/en active Pending
- 2020-04-20 PE PE2021001736A patent/PE20212368A1/es unknown
- 2020-04-20 BR BR112021018325A patent/BR112021018325A2/pt unknown
- 2020-04-20 AU AU2020261941A patent/AU2020261941B2/en active Active
- 2020-04-20 KR KR1020217034137A patent/KR102832458B1/ko active Active
-
2021
- 2021-10-14 CL CL2021002690A patent/CL2021002690A1/es unknown
- 2021-10-20 CO CONC2021/0014034A patent/CO2021014034A2/es unknown
- 2021-10-26 EC ECSENADI202179422A patent/ECSP21079422A/es unknown
-
2023
- 2023-03-13 JP JP2023038306A patent/JP7615426B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005515A (es) | Formulaciones de polvo nasal para el tratamiento de la hipoglicemia | |
| AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| WO2019087083A3 (en) | Oral delivery of glp-1 peptide analogs | |
| CU20210077A7 (es) | Extractos bacterianos estables como fármacos | |
| MX2021006969A (es) | Ligante peptidico. | |
| ECSP21060917A (es) | Formulación de anticuerpos terapéuticos | |
| WO2021118930A3 (en) | Anti-pd-l1 antibody formulations | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| MX2020010085A (es) | Formulaciones que contienen péptidos. | |
| ECSP21079422A (es) | Método para preparar formulaciones de péptidos estables | |
| JOP20170127A1 (ar) | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات | |
| WO2020013777A3 (en) | Tablet formulations comprising metformin and sitagliptin | |
| SA520420369B1 (ar) | تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي | |
| MX2020000144A (es) | Composicion farmaceutica para administracion nasal. | |
| MX2021015930A (es) | Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1. | |
| NI202000095A (es) | Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión | |
| WO2020055359A3 (en) | Oral dosage form of sorafenib tosylate | |
| CY1125336T1 (el) | Μια φαρμακευτικη συνθεση ξηρης σκονης για εισπνοη που περιλαμβανει μια θυρεοειδικη ορμονη | |
| CL2022001085A1 (es) | Formulación de anticuerpo que contiene crizanlizumab | |
| MY209184A (en) | Stability of vitamin d in eta-hydroxy- eta-methylbutyrate (hmb) | |
| EA202191327A1 (ru) | Лекарственные формы терапевтических препаратов от гриппа |